Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Nilsine Partners LLC

Nilsine Partners LLC grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 82.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,585 shares of the medical equipment provider's stock after purchasing an additional 5,696 shares during the quarter. Nilsine Partners LLC's holdings in Intuitive Surgical were worth $6,233,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Brighton Jones LLC boosted its position in Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after acquiring an additional 731 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new stake in Intuitive Surgical during the fourth quarter worth approximately $6,509,000. Bank of Stockton boosted its position in Intuitive Surgical by 13.5% during the fourth quarter. Bank of Stockton now owns 1,161 shares of the medical equipment provider's stock worth $606,000 after acquiring an additional 138 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its position in Intuitive Surgical by 0.5% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock worth $99,678,000 after acquiring an additional 883 shares during the last quarter. Finally, Meitav Investment House Ltd. acquired a new stake in Intuitive Surgical during the fourth quarter worth approximately $209,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Intuitive Surgical news, EVP Gary Loeb sold 1,700 shares of the business's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $513.18, for a total transaction of $872,406.00. Following the sale, the executive vice president now directly owns 2,245 shares in the company, valued at approximately $1,152,089.10. The trade was a 43.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mark Brosius sold 216 shares of the business's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president now owns 907 shares in the company, valued at $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 4,998 shares of company stock valued at $2,611,577. Company insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on ISRG shares. Citigroup restated a "buy" rating and set a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Truist Financial cut their price target on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Robert W. Baird cut their price target on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Piper Sandler cut their price target on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. Finally, Erste Group Bank raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Thursday, June 5th. One analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $588.95.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $509.36 on Friday. The firm has a market cap of $182.56 billion, a P/E ratio of 74.69, a P/E/G ratio of 5.40 and a beta of 1.67. Intuitive Surgical, Inc. has a 1-year low of $413.82 and a 1-year high of $616.00. The firm has a fifty day moving average of $528.03 and a two-hundred day moving average of $537.47.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. The business had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same period in the previous year, the business posted $1.50 EPS. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.